Results 1 to 10 of about 9,119 (116)

Ramucirumab as Second-Line Treatment in Chinese Patients With Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein After Sorafenib (REACH-2 China): A Randomised, Multicentre, Double-Blind Study

EClinicalMedicine, 2022
Summary: Background: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP).
Kangsheng Gu, Ryan C Widau, Yabing Guo
exaly   +3 more sources

Reduced-dose nanoparticle albumin-bound-paclitaxel combined with ramucirumab as second-line treatment for advanced gastric cancer: a multicenter phase II study [PDF]

BMC Cancer
Background Weekly paclitaxel combined with ramucirumab is the standard second-line chemotherapy regimen for advanced gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is increasingly used as it lowers the risk of hypersensitivity ...
Michihisa Iida, Chiyo Nakashima, Toru Kawaoka, Junya Kondo, Tsunenori Yamamoto, Shigefumi Yoshino, Kazuhisa Tokuno, Takayuki Kuga, Koji Dairaku, Yuki Nakagami, Yusaku Watanabe, Hiroto Matsui, Yoshitaro Shindo, Hidenori Takahashi, Tatsuya Ioka, Hiroaki Nagano   +15 more
doaj   +2 more sources

Effect of ramucirumab and bevacizumab in an experimental diabetic retinopathy rat model: A pilot study [PDF]

Indian Journal of Ophthalmology
Purpose: To compare the biochemical and histopathological effects of ramucirumab and bevacizumab in a streptozotocin (STZ)-induced experimental diabetic retinopathy (DR) rat model.
Sara Koylu Güngör, Sabiha Güngör Kobat², Mehmet Balbaba², Hakan Yıldırım², Nevin İlhan, Yesarı Eroksuz   +5 more
doaj   +2 more sources

Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study [PDF]

Thoracic Cancer
Background Malignant pleural effusion (MPE) is associated with a poor prognosis and quality of life in patients with non‐small cell lung cancer (NSCLC).
Meiko Morita, Kazushige Wakuda, Suguru Matsuda, Motoki Sekikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi   +14 more
doaj   +2 more sources

Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer

Journal of the Formosan Medical Association, 2022
Background: Ramucirumab is indicated for salvage treatment after failure of first-line treatment for metastatic colorectal cancer (mCRC). However, the application of ramucirumab at later-line treatment in real-world practice has not received much ...
Yi-Hsin Liang, Jin-Tung Liang, Ben-Ren Lin, John Huang, Ji-Shiang Hung, Shuo-Lun Lai, Tzu-Chun Chen, Jia-Huei Tsai, Yung-Ming Cheng, Ting-Han Tsao, Wen-Ling Hsu, Kuo-Hsing Chen, Kun-Huei Yeh   +12 more
doaj   +1 more source

Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

BMC Gastroenterology, 2023
Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial.
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato   +31 more
doaj   +1 more source

Tracheoesophageal fistula and esophageal perforation in a patient with advanced gastroesophageal junction tumor post ramucirumab treatment. A case report and literature review

Current Problems in Cancer: Case Reports, 2023
Background: Ramucirumab is an anti-angiogenic drug that received Food and Drug Administration (FDA)-approvals for treatments of many cancers. Gastrointestinal fistulas and perforations are recognized side effects of anti-angiogenic therapies, however ...
Ahmed Abdalhadi, Mouhammad J Alawad, Nabil E. Omar, Muhammed Hajmusa, Mohammed Gaber, Alaaeldin Shablak   +5 more
doaj   +1 more source

A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice

Медицинский совет, 2020
Ramucirumab is a human anti-vascular endothelial growth factor receptor 2(VEGFR-2)monoclonal antibodythat acts on vascular endothelial cells to inhibit angiogenesis.
T. A. Titova, N. S. Besova, E. A. Artamonova   +2 more
doaj   +1 more source

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

BMC Cancer, 2023
Background Recent reports suggested combining ramucirumab with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to overcome EGFR resistance in non–small cell lung cancer (NSCLC).
Chun-Yao Huang, Hui-Li Huang, Chou-Chin Lan, Yi-Chih Huang, Yao-Kuang Wu   +4 more
doaj   +1 more source

Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population

Life, 2023
(1) Background: Following the results of RAINBOW and REGARD trials, ramucirumab was approved as the standard second-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, alone or in combination with ...
Diana Galos, Loredana Balacescu, Radu Vidra, Daniel Sur   +3 more
doaj   +1 more source